1. Clinical & Scientific Overview
Niacinamide (Vitamin B3 Cosmetic Grade) (TIP-MED-000605, Reference Code [COS-01]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Skin Conditioning Agent, Barrier Lipid Booster & Sebum Regulator.
Within the Indian regulatory and compendial framework, it is governed under Cosmetic ingredient under the Cosmetics Rules, 2020 (CDSCO) and IS 4707 (Part 2); strictly cosmetic — must not claim drug treatment of rosacea or melasma..
INCI Standard: Niacinamide (IS 4707 / Cosmetics Rules, 2020 Compliant)
2% to 5% (optimal evidence-backed concentration; >10% increases flushing/irritation without added efficacy); pH 5.5–7.0
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
NiacinamideSkin Conditioning Agent, Barrier Lipid Booster & Sebum Regulator
2% to 5% (optimal evidence-backed concentration; >10% increases flushing/irritation without added efficacy); pH 5.5–7.0
Irritation, Sensitisation & Photoprotection Considerations: Well tolerated at 2–5%; concentrations >=10% or pH <4.0 (which hydrolyses niacinamide into nicotinic acid/niacin) trigger prostaglandin D2-mediated facial flushing, erythema, and stinging.
Chemical Stability & Formulation Incompatibilities: Incompatible with strong acids (pH <3.5) and pure L-Ascorbic Acid at high temperatures (forms yellow niacinamide ascorbate charge-transfer complex and hydrolyses to irritating nicotinic acid).
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic ingredient under the Cosmetics Rules, 2020 (CDSCO) and IS 4707 (Part 2); strictly cosmetic — must not claim drug treatment of rosacea or melasma.
3. Mechanism of Action & Pharmacodynamics
Water-soluble pyridinecarboxamide that serves as a precursor to epidermal NAD+/NADP+ coenzymes, stimulating de novo synthesis of ceramides, free fatty acids, and cholesterol in the stratum corneum while inhibiting melanosome transfer from melanocytes to keratinocytes and reducing sebaceous lipogenesis.
4. Therapeutic Indications & Evidence-Supported Uses
- Epidermal barrier strengthening in xerosis and sensitive skin
- Adjunct cosmetic care for acne-prone skin and post-inflammatory hyperpigmentation
- Photoageing fine-line appearance reduction
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: 2% to 5% (optimal evidence-backed concentration; >10% increases flushing/irritation without added efficacy); pH 5.5–7.0
Administration & Meal Timing: External topical use only (2% to 5% (optimal evidence-backed concentration; >10% increases flushing/irritation without added efficacy); pH 5.5–7.0). Incompatible with strong acids (pH <3.5) and pure L-Ascorbic Acid at high temperatures (forms yellow niacinamide ascorbate charge-transfer complex and hydrolyses to irritating nicotinic acid).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Niacinamide
- Application to open wounds, abraded skin, or acute infectious dermatoses
- Well tolerated at 2–5%; concentrations >=10% or pH <4.0 (which hydrolyses niacinamide into nicotinic acid/niacin) trigger prostaglandin D2-mediated facial flushing, erythema, and stinging.
Key Clinical Precautions: Well tolerated at 2–5%; concentrations >=10% or pH <4.0 (which hydrolyses niacinamide into nicotinic acid/niacin) trigger prostaglandin D2-mediated facial flushing, erythema, and stinging.
8. Adverse Effects Profile
- Well tolerated at 2–5%; concentrations >=10% or pH <4.0 (which hydrolyses niacinamide into nicotinic acid/niacin) trigger prostaglandin D2-mediated facial flushing, erythema, and stinging.
- Well tolerated at 2–5%; concentrations >=10% or pH <4.0 (which hydrolyses niacinamide into nicotinic acid/niacin) trigger prostaglandin D2-mediated facial flushing, erythema, and stinging.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Incompatible with strong acids (pH <3.5) and pure L-Ascorbic Acid at high temperatures (forms yellow niacinamide ascorbate charge-transfer complex and hydrolyses to irritating nicotinic acid).
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Incompatible with strong acids (pH <3.5) and pure L-Ascorbic Acid at high temperatures (forms yellow niacinamide ascorbate charge-transfer complex and hydrolyses to irritating nicotinic acid).
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Incompatible with strong acids (pH <3.5) and pure L-Ascorbic Acid at high temperatures (forms yellow niacinamide ascorbate charge-transfer complex and hydrolyses to irritating nicotinic acid).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.